Tag

Status Conference Archives - Carey Danis & Lowe

Transvaginal Mesh Lawsuits Move Forward against American Medical Systems, as Federal Court Issues Order for Third Round of Trials

By | Defective Medical Device litigation, Transvaginal Mesh, Uncategorized

Published May 19, 2014 by Digital Journal

Anterior-Vaginal-MeshThousands of transvaginal mesh lawsuits filed against American Medical Systems, Inc. continue to move forward in a consolidated litigation underway in U.S. District Court, Southern District of West Virginia. On May 16, 2014, the Court approved a new Docket Control Order pertaining to the litigation’s third round of bellwether trials. Among other things, the Order stipulates that all discovery, including depositions of all company witnesses and third parties, will be completed by July 14, 2014. Dates for pretrial and settlement conferences, as well as the start date for the trial itself, will be determined by the Court at a future Status Conference. (In Re American Medical Systems, Inc. – MDL No. 2325)

Vaginal Mesh Lawsuits

According to court documents, tens of thousands of vaginal mesh lawsuits have been filed against American Medical Systems in courts around the country. The vast majority of claims are pending in the Southern District of West Virginia, where Jeffrey S. Grand is serving on the Plaintiffs’ Steering Committee.

On April 30, 2014, Endo International PLC, the parent company of American Medical Systems, announced a settlement agreement that could potentially resolve some 20,000 transvaginal mesh lawsuits pending against the company. Among other things, Endo indicated that it has set aside $830 million to cover the settlement agreement, which is expected to be implemented over the next year. Endo did not admit liability or fault for any plaintiffs’ alleged vaginal mesh complications in agreeing to the settlement plan.*

According to court filings, American Medical Systems is just one of several companies named in vaginal mesh lawsuits in the Southern District of West Virginia. In addition to his work on that litigation, Mr. Grand is also serving on the Plaintiffs’ Steering Committees in several proceedings established in that jurisdiction that involve Boston Scientific Corp., (MDL 2326), C.R. Bard, Inc. (MDL 2325) and Ethicon, Inc. (MDL No. 2327).

Mr. Grand is also serving as Co-Liaison Counsel in two consolidated proceedings established for C.R. Bard and Ethicon mesh lawsuits in New Jersey’s Atlantic Superior Court. He was also a member of the plaintiff’s trial team for the first Ethicon trial, which ended in March with an $11 million verdict for the Plaintiff. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10).

Alleged victims of serious vaginal mesh complications may be entitled to compensation for their injury-related damages. To learn more about filing a transvaginal mesh lawsuit, please visit Carey Danis & Lowe’s website https://www.careydanis.com. To obtain a free, confidential and no-obligation case review, please call 1.800.721.2519.

 

C.R. Bard Mesh Lawsuit News: December Status Conference Canceled

By | Defective Medical Device litigation, Transvaginal Mesh, Uncategorized

cr_bard_transvaginal_mesh_lawsuit_claims_settlementsCarey Danis & Lowe continues to follow the C.R. Bard multidistrict litigation (MDL) in a West Virginia federal court. In a court document filed in early December, Judge Joseph R. Goodwin, who is presiding over the C.R. Bard MDL, as well as the other five transvaginal mesh MDLs in the West Virginia federal court, announced that December’s status conference is canceled.

The court was scheduled to convene on December 5. With that meeting having been annulled, the next status conference in the C.R. Bard MDL will be on January 9, 2014.

In addition to the cancellation announcement, the court also filed a document relating to one particular case filed in the MDL that contains more than one plaintiff. The case is civil action no. 2:13-cv-29861.

Judge Goodwin ruled that in this particular case, because the plaintiffs have no relation to one another aside from their receiving a C.R. Bard transvaginal mesh implant, their cases must be separated, called a severance of actions. The plaintiffs who are not named first in the case will have their claims removed from the MDL, but they will have the opportunity to resubmit their claims as separate lawsuits to the C.R. Bard MDL.

The C.R. Bard MDL is being heard in the U.S. District Court for the Southern District of West Virginia. The MDL is known as In re: C.R. Bard, Inc., Pelvic Repair System Products Liability Litigation MDL no. 2187.

As a national law firm that represents victims of transvaginal mesh, Carey Danis & Lowe is the legal source to rely upon for the most current information on the C.R. Bard MDL, as well as the other five transvaginal mesh MDLs being heard in West Virginia.

If you have been harmed by transvaginal mesh, know that Carey Danis & Lowe is available to discuss your legal options, to provide you with a free initial consultation, and to assist you with filing a transvaginal mesh lawsuit.

In addition, Carey Danis & Lowe has a team of on-staff nurses that are available to answer any of your questions relating to transvaginal mesh injuries.

Share your transvaginal mesh story with Carey Danis & Lowe. Call us at 800.721.2519, or by completing a confidential personal injury claim form.

Stay current on the latest transvaginal mesh lawsuit news by reading the Carey Danis & Lowe personal injury litigation blog.

Transvaginal Mesh Lawsuit Update: West Virginia MDLs Met Mid-September for Status Conference

By | Defective Medical Device litigation, Transvaginal Mesh, Uncategorized

transvaginal_mesh_lawsuit_settlements_news_mdl_class_action_lawsuit_vaginal_mesh_lawsuit_erosion_pain_bleedingThere are six transvaginal mesh multidistrict litigations (MDLs) being heard by U.S. District Judge Joseph R. Goodwin in the U.S. District Court for the Southern District of West Virginia. The court convened in mid-September for a status conference to discuss progress in all six of the transvaginal mesh MDLs.

Both parties discussed the deadline for filing transvaginal mesh lawsuits. Judge Goodwin stated that he would mull over a deadline extension and flexibility on the weekly filing allowance.

The plaintiffs counsel and defendants counsel also discussed progress being made in the bellwether trial process. According to the status conference minutes, the next bellwether trial among the six transvaginal mesh MDLs will be Jones v. C. R. Bard, scheduled to begin on November 12, 2013.

In the American Medical Systems MDL, the first bellwether trial was scheduled for December 2013, but has been delayed with a new start date yet to be decided.

The six transvaginal mesh MDLs are:

  • In re: C. R. Bard, Inc., Pelvic Repair System Products Liability Litigation MDL No. 2187
  • In re: American Medical Systems, Inc., Pelvic Repair System Products Liability Litigation MDL No. 2325
  • In re: Boston Scientific Corp., Pelvic Repair System Products Liability Litigation MDL No. 2326
  • In re: Ethicon Inc., Pelvic Repair System Products Liability Litigation MDL No. 2327
  • In re: Coloplast Corp. Pelvic Support Systems Products Liability Litigation MDL No. 2387
  • In re: Cook Medical, Inc., Pelvic Repair System Products Liability Litigation MDL No. 2440

According to the U.S. Food and Drug Administration (FDA), patients who experienced an adverse effect from transvaginal mesh most often reported mesh erosion as being the complication. Transvaginal mesh erosion occurs when the mesh begins eroding surrounding tissue and organs. The FDA has also reviewed a number of adverse event reports wherein the patient experienced infection, bleeding, and painful intercourse associated with a transvaginal mesh implant.

The team of St. Louis class action attorneys at Carey Danis & Lowe work diligently to win you or your loved one a day in court, so that your transvaginal mesh case can finally be heard. Work with one of our transvaginal mesh lawyers, and receive a free legal evaluation of your transvaginal mesh case. Carey Danis & Lowe can also assist with evaluating your compensation eligibility and with filing a transvaginal mesh lawsuit.

Share your story with Carey Danis & Lowe by calling 800.721.2519, or by submitting a personal injury claim form.

Pradaxa MDL News: Court Convened for Status Conference in Early February

By | Pharmaceutical litigation, Pradaxa, Uncategorized

pradaxa4The Pradaxa multi-district litigation (MDL) met in early February for a status conference to discuss recent progress made in the discovery and deposition processes. According to Seth A. Katz, one of the lawyers representing the plaintiffs in the Pradaxa MDL, Boehringer Ingelheim Pharmaceuticals Inc. has not been meeting production deadlines.

According to the Pradaxa MDL status conference minutes, the plaintiffs asked for certain documents to be produced by Boehringer Ingelheim, the pharmaceutical company that develops and manufactures Pradaxa, an anticoagulant medicine prescribed to patients with non-valvular atrial fibrillation.

These document requests were made in late December and in mid-January. As of yet, these documents have been provided to neither the plaintiffs nor their legal counsel. Since then, the plaintiffs have voiced concern about whether Boehringer Ingelheim will transmit these custodial files to the plaintiffs for review.

The discovery phase in the Pradaxa MDL is important for the plaintiffs and their legal counsel in that it allows them to review the documents provided by Boehringer Ingelheim, and in doing so, build a case around the evidence presented in these internal documents.

To date, approximately 258 cases have been consolidated into the Pradaxa MDL. These consolidated cases are being heard in the U.S. District Court for the Southern District of Illinois. The Pradaxa MDL is known as in Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation MDL no. 2385. Chief Judge David R. Herndon is presiding over court proceedings.

The court minutes state that the next status conference in the Pradaxa MDL has been scheduled for March 14.

Pradaxa has gained a reputation for causing serious bleeding events that can be fatal. Patients with atrial fibrillation have used Pradaxa to prevent stroke and blood clots. However, Pradaxa has not worked as designed, and has led to a severe bleeding events and numerous deaths.

Boehringer Ingelheim’s anticoagulant medicine was intended to replace warfarin, a drug introduced in the 1950s. Pradaxa has proved to be an insufficient replacement, if it can even be considered a replacement.

An enormous complication with the use of Pradaxa is that it does not have a reversal agent, meaning a medicine that can be ingested to reverse the blood thinning properties present in Pradaxa. Unlike warfarin, Boehringer Ingelheim released Pradaxa onto the market without a panacea for serious bleeding events. The reversal agent for warfarin is Vitamin K.

The defective drug and Pradaxa lawyers at Carey Danis & Lowe continue to follow the Pradaxa MDL in East St. Louis for any updates that may benefit our Pradaxa clients. Carey Danis & Lowe is accepting Pradaxa claims, and offering free legal consultations about Pradaxa cases.

If you or someone you love has been injured by Pradaxa, you and your loved one may be eligible to receive compensation. To file a Pradaxa lawsuit, contact a Pradaxa lawyer at Carey Danis & Lowe today by calling 800.721.2519 or submit a legal claim form.

Update on Ethicon MDL in U.S. District Court: Over 3000 Plaintiffs Vaginal Mesh Lawsuits Consolidated into MDL

By | Defective Medical Device litigation, Transvaginal Mesh, Uncategorized

Update on Ethicon MDL in U.S. District Court: Over 3000 Plaintiffs Vaginal Mesh Lawsuits Consolidated into MDL Approximately 3397 cases have been consolidated into the Ethicon multi-district litigation (MDL) being heard in the U.S. District Court for the Southern District of West Virginia. The Ethicon MDL is being presided over by U.S. District Judge Joseph R. Goodwin.

In the last pre-trial court order issued by Judge Goodwin, a minor update was given pertaining to the format of the Plaintiff Profile Form, which are documents that release a plaintiff’s medical records for examination.

The next Status Conference in the Ethicon MDL will be held on March 21, 2013.

The Ethicon MDL is being heard in the same U.S. District Court as four other MDLs pertaining to vaginal mesh manufacturers. Each of these vaginal mesh MDLs are being presided over by Judge Joseph R. Goodwin. The four other vaginal mesh MDLs include cases brought against C.R. Bard, Inc., American Medical Systems, Inc., Boston Scientific Corp., and Coloplast Corp.

Though many decisions made in one vaginal mesh MDL sometimes impact the other vaginal mesh MDLs being heard by Judge Goodwin, the most recent pre-trial order delivered in the Ethicon MDL pertains only to this specific MDL.

Ethicon, Inc. is an arm of Johnson & Johnson, which developed and manufactured the Gynecare Prolift vaginal mesh. Plaintiffs in the Ethicon MDL received a implant of the Gynecare Prolift in order to correct conditions known as stress urinary incontinence (SUI) or pelvic organ prolapse (POP). The Gynecare Prolift vaginal mesh has been connected to serious health complications, including infections, vaginal erosion, organ perforation, pelvic region pain, painful intercourse, and vaginal discharge and bleeding.

Johnson & Johnson announced in June 2012 that it would pull four of its vaginal mesh products from the worldwide market. These four vaginal mesh products include the Gynecare Prolift as well as the Prosima Pelvic Floor Repair System, the Prolift+M Gynemesh M, and the Gynecare TVT Secur System.

When discussing its reasons for pulling its surgical mesh off the market, a Johnson & Johnson spokesperson speaking with Reuters stated that Johnson & Johnson was discontinuing sales as opposed to recalling the vaginal mesh products. No reference was made by Johnson & Johnson to the health complications, especially vaginal erosion, linked with use of their vaginal mesh products.

Lawyers at Carey Danis & Lowe have been examining Gynecare Prolift cases as the Ethicon MDL in West Virginia continues to grow larger and move farther into pre-trial proceedings. During this examination process, our lawyers have been offering free evaluations of Gynecare Prolift cases.

If you or someone you love has been injured after receiving an implant of Ethicon’s Gynecare Prolift vaginal mesh, contact a lawyer at Carey Danis & Lowe at 800.721.2519 for more information about filing a Gynecare Prolift vaginal mesh lawsuit.

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in Louisiana

By | Actos, Pharmaceutical litigation, Uncategorized

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in LouisianaParties involved in the Actos multi-district litigation (MDL) in the U.S. District Court for the Western District of Louisiana met for a Status Conference on January 24, 2013. The MDL is known as in re: Actos (Pioglitazone Products Liability Litigation) MDL No. 11-md-2299, and is being presided over by U.S. District Judge Rebecca F. Doherty.

During the most recent Actos MDL Status Conference, the court reviewed recent Actos filings in federal and state courts as well as any new developments since the Actos MDL’s last Status Conference in December 2012. According to an Actos MDL court document, the parties also discussed the progress of the discovery phase. The next Status Conference is scheduled for February 21, 2013.

Plaintiffs whose cases have been consolidated into the Actos MDL have filed their lawsuits against the manufacturer of Actos claiming that the drug caused serious health complications, including bladder cancer.

In a study conducted by Takeda Pharmaceuticals in collaboration with Kaiser Permanente, data shows an increased risk in the development of bladder cancer in patients who have been using Actos for more than 1 year. At this time, the FDA is reviewing information from the Takeda and Kaiser Permanente ten year study. In Europe, healthcare officials have banned sales of Actos following data released from a French epidemiological study that showed a strong link between the ingestion of Actos and the development of bladder cancer.

In other Actos related news, the manufacturer of Actos has received approval to sell a new diabetes drug in the U.S. According to a Bloomberg News report, the Japanese manufacturer of Actos, Takeda Pharmaceuticals, just received approval from the U.S. Food and Drug Administration (FDA) for a new diabetes medication known generically as alogliptin. Takeda Pharmaceuticals intends to market alogliptin in the U.S. by the brand name of Nesina.

Over a five year period, the FDA rejected the new diabetes medication twice before finally granting it approval this month. Whether this new diabetes drug comes with the risk of developing bladder cancer is still uncertain.

Lawyers at Carey Danis & Lowe are currently evaluating Actos claims. If you or someone you love has taken Actos and has subsequently developed bladder cancer, you may be eligible to receive recompense for your pain, suffering, medical expenses, and lost wages.

For a free legal evaluation about your Actos claim and to learn more about filing an Actos bladder cancer lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe at 800.721.2519 today.

Carey Danis & Lowe Issues an Update on the Pradaxa Multi-District Litigation No. 2385

By | Pharmaceutical litigation, Pradaxa, Uncategorized

Published December 27, 2012 by PR Web

St. Louis, MO (PRWEB) December 27, 2012

Carey Danis & Lowe Issues an Update on the Pradaxa Multi-District Litigation No. 2385Pradaxa lawsuits have been consolidated into a Multi-District Litigation being heard in the U.S. District Court, Southern District of Illinois. The Pradaxa MDL has been named Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation. The last Pradaxa MDL meeting occurred on Thursday, December 13, 2012, where Plaintiffs’ representatives as well as the Defendants’ legal counsel convened for a Status Conference.

The MDL No. 2385 is presided over by Chief Judge David R. Herndon in East St. Louis, Illinois. The MDL is currently in the pre-trial discovery phase.

As outlined in the court’s minutes, both sides have been working to approve the First and Second Sets of Discovery gathered by the Plaintiffs legal representatives. Though the two side came to a written agreement on the Second Set of Discovery, in regards to the First, the Plaintiffs’ legal representatives have been working “to resolve pending disputes.”

According to the Pradaxa MDL 2835 Status Conference minutes from December 13, the Plaintiffs’ First Set of Discovery has resulted in a number of unsettled disagreements between the Plaintiffs Lead Counsel and Boehringer Ingelheim Pharmaceuticals, Inc. As court documents detail, Boehringer Ingelheim has objections with regard to the Plaintiffs Lead Counsel’s First Set of Discovery.

As a result of the yet unresolved issues with the First Set of Discovery, Boehringer Ingelheim is filing a protective order, and plans to do so by December 21, 2012. In response to the protective order and in an effort to acquire vital evidence and documents, the Plaintiffs Lead Counsel plans to file a responsive pleading early next year.

Currently, over 170 plaintiffs have a case that has been consolidated into MDL No. 2385. These plaintiffs claim that the ingestion of Pradaxa led to serious Pradaxa-related injuries including excessive bleeding, uncontrollable bleeding, and fatal bleed-outs. Furthermore, these Pradaxa lawsuits claim that Boehringer Ingelheim neglected to warn healthcare providers and patients about the risks of using Pradaxa.

In addition, plaintiffs accuse Boehringer Ingelheim of further negligence in light of Pradaxa’s release onto the market without the simultaneous release of a reversal agent which is vital in treating excessive bleeding. Unlike warfarin which is counteracted by Vitamin K in excessive bleeding episodes, Pradaxa has no known panacea or reversal agent to control excessive bleeding.

Attorneys at Carey Danis & Lowe are currently seeking claims from individuals who have experienced a Pradaxa injury, including those listed above, such as excessive and uncontrollable bleeding events. For more information about filing a Pradaxa lawsuit, contact a defective drug lawyer at Carey Danis & Lowe at 800-721-2519.

Pradaxa Lawsuit News: Pradaxa MDL Convened in District Court in Illinois for Status Conference on January 14, 2013

By | Pharmaceutical litigation, Pradaxa, Uncategorized

Pradaxa Lawsuit News: Pradaxa MDL Convened in District Court in Illinois for Status Conference on January 14, 2013Court convened in the Pradaxa Multi-District Litigation (MDL) known as In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation) MDL No. 2385 for a Status Conference on January 14, 2013. The Pradaxa MDL is being heard in the U.S. District Court for the Southern District of Illinois in East St. Louis, and is being presided over by Chief Judge David R. Herndon.

An attorney on the Plaintiffs’ Co-Lead Counsel, Roger C. Denton, delivered an update on the development of a Privilege Log, a document listing items to be withheld during legal proceedings. Both parties have come to an agreement on what items to list on the Privilege Log as well as when Boehringer Ingelheim is scheduled to begin delivering items for the Privilege Log to the plaintiffs’ counsel.

Boehringer Ingelheim’s lawyers supplied an update on defense witness depositions, which have been scheduled for March. According to the Pradaxa MDL Status Conference minutes, both parties are working on scheduling these depositions, but have come across obstacles in determining deposition locations.

To date, there are 183 cases that have been consolidated into the Pradaxa MDL in East St. Louis, Illinois.

Pradaxa is an anticoagulant drug prescribed to patients with non-valvular atrial fibrillation. As an anticoagulant medication, Pradaxa was developed by Boehringer Ingelheim Pharmaceuticals, Inc. with the expectation that the drug would be a superior alternative to warfarin, an anticoagulant drug introduced in the 1950s.

Upon authorizing approval of the drug Pradaxa in October 2010, the U.S. Food and Drug Administration (FDA) began receiving adverse event reports, and more specifically, patient reports detailing episodes of severe and uncontrollable bleeding linked to the use of Pradaxa. As a result of these serious bleeding risk reports, the FDA continues to research the health risks of ingesting Pradaxa in the prevention of strokes and blood clots in patients with atrial fibrillation.

Lawyers at Carey Danis & Lowe are currently accepting Pradaxa claims, and are working on evaluating each Pradaxa lawsuit for inclusion in the MDL in East St. Louis, Illinois. If you or someone you love has suffered a severe bleeding event while taking Pradaxa, you and your loved one may be eligible to receive recompense for such undue suffering.

To submit a Pradaxa claim and for a free legal consultation regarding your Pradaxa case, contact an experienced trial lawyer at Carey Danis & Lowe by calling 800.721.2519.

Actos MDL 2299 Update: Periodic Review Established and Next Status Conference Scheduled

By | Actos, Pharmaceutical litigation, Uncategorized

Actos MDL 2299 Update: Periodic Review Established and Next Status Conference ScheduledAn Actos Multi-District Litigation (MDL) has been consolidated in Louisiana as of December 2011. The Actos MDL is being heard by U.S. District Judge Doherty in the U.S. District Court for the Western District of Louisiana. The MDL has been named In Re: Actos (Pioglitazone) Products Liability Litigation MDL No. 2299.

The most recent news coming from the Actos MDL regards an administrative order outlining how the MDL will be conducted. The Case Management Order, delivered on January 2, 2013, details nothing of the MDL’s purpose, but rather outlines a periodic review process. The reason for making arrangements for a periodic review is to give attorneys involved in the MDL, on both sides, the opportunity and ability to share ideas, updates, and recommendations pertaining to the how the MDL is administered.

The next Status Conference for the Actos MDL 2299 will be January 24, 2013.

Actos is a drug manufactured by Takeda Pharmaceuticals, and is prescribed to patients with type 2 diabetes. The drug was approved for use in the U.S. by the  U.S. Food and Drug Administration (FDA) in July 1999.

According to a CBS News report from June 2011, the French Medicines Agency banned sales of Actos after reviewing data gathered in a French government funded epidemiological study demonstrated a strong link between the use of Actos and the development of bladder cancer. Soon after France banned Actos, German health officials followed suit in banning new prescriptions of the drug to diabetic patients.

In America, the FDA is continues to review the safety of Actos. Upon parsing through interim data from a 10 year study being funded by Takeda Pharmaceuticals in collaboration with Kaiser Permanente Northern California, the FDA issued an Actos safety update in August 2011 about the increased risk of developing Actos linked bladder cancer after using the drug for more than one year. Though the FDA recognizes the risks of using Actos, their safety review remains ongoing.

Signs of bladder cancer include painful urination, red colored urine, blood in urine, severe pain in the pelvic region, and frequent need to urinate. If you or a loved one is currently using Actos or has used Actos in the past to treat type 2 diabetes, and you or your loved one has experienced any of these signs of bladder cancer, it is imperative to meet with a healthcare provider immediately.

Experienced pharmaceutical product liability lawyers at Carey Danis & Lowe understand the importance of holding pharmaceutical companies like Takeda Pharmaceuticals accountable for releasing drugs onto the market whose side effects have not been fully researched. It was only after Actos was on the market, and only after reports began piling up relating to Actos bladder cancer risks, did Takeda Pharmaceuticals decide to conduct a 10 year study looking into the safety of Actos.

Lawyers at Carey Danis & Lowe seek to work closely with clients in shedding light on such negligence. For a free legal consultation about your Actos case, and for more information about filing an Actos lawsuit, contact a lawyer at Carey Danis & Lowe by calling 800.721.2519.

Levaquin MDL Settlement Update: Phase 1 Plaintiffs Have Signed a Settlement Agreement

By | Levaquin, Pharmaceutical litigation, Uncategorized

Levaquin MDL Settlement Update: Phase 1 Plaintiffs Have Signed a Settlement AgreementCourt convened on January 8, 2013 for a Status Conference for Levaquin lawsuits that have been consolidated into In Re: Levaquin Products Liability Litigation, the Multi-District Litigation (MDL) that is being heard by U.S. District Judge John R. Tunheim in the U.S. District Court for the District of Minnesota. Though the plaintiffs’ committee and the defendant’s representation only met for a half hour, they brought forth important updates in the Levaquin MDL.

According to information provided by the Defendants, there are currently 1000 cases pending in the Levaquin MDL “that are in the process of settling, and will soon be dismissed.” Once the settlement of these 1000 cases is complete, the Levaquin MDL will consist of 900 cases.

In state Levaquin lawsuits, there is a mass tort litigation that has been established in a New Jersey state court with 1400 cases that remain open. Further updates about the New Jersey mass tort Levaquin litigation will be available after the next Status Conference, which is scheduled for January 25. To date, the New Jersey mass tort Levaquin litigation represents the most Levaquin lawsuits being heard by a state court.

As the Levaquin MDL Status Conference minutes detail, there are “three cases pending in Illinois…one case in Pennsylvania and one in Mississippi.”

As to the status of settlement negotiations in the Levaquin MDL, both parties have come to a settlement agreement in Phase 1 cases. The plaintiffs with cases consolidated into the Phase 1 pool have signed the settlement agreement.

The plaintiffs’ committee has since begun work on plans to allocate the settlement funds. For cases consolidated into Phase 2 and Phase 3 pools, both parties are still working on negotiating a settlement agreement.

Levaquin is a drug manufactured by OrthoMcNeil Pharmaceutical, Inc., a Johnson & Johnson subsidiary, that is prescribed to patients suffering from a bacterial infection of the lungs, skin, and urinary tract. Some patients who were prescribed Levaquin, and subsequently ingested the drug to treat their bacterial infection, experienced serious side effects.

The drug Levaquin has been known to inflict severe tendon damage, including tendon inflammation, tendonitis, joint immobility, and tendon rupture.